Development of autologous in vitro vascular models for use in preclinical biotherapeutic development
Blood Vessels, Thrombosis & Hemostasis · 2026-05 · 3 (2) · 100143
DOI: 10.1016/j.bvth.2026.100143 ↗Kurz gefasst
Fachartikel in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2026-05. Verfasst von Emma Lund und 7 weiteren Autor:innen. Beteiligte Einrichtung: Labcorp, Harrogate, United Kingdom. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Imperial College London.
Abstract (Originalsprache)
Following previous failures to predict drug-induced adverse immune reactions in clinical trials, for example in cases with preclinical species differences or poorly indicative in vitro assays, there has been an emphasis on developing improved preclinical hazard identification tools. Concurrently, there is a regulatory agency-backed responsibility to reduce reliance on preclinical animal models, highlighted by the Food and Drug Administration (FDA) Modernization Act 2.0 and the FDA's 2025 announcement to phase out animal testing for specific compounds. Traditional in vitro cytokine release assays utilize plastic-based formats of antibody presentation to blood cell fractions, and, although biologically simple to run, they do not accurately recapitulate in vivo blood vessel physiology. Including endothelial cells improves physiological relevance by representing the internal vascular wall, enabling cell-cell interactions, compound presentation, and cellular responses from endothelial cells alongside blood cells. Here, endothelial cells outgrown from healthy donors were cocultured with their blood cells to model the immune response to compounds. Building on existing endothelial assays cocultured with blood cell fractions, we established the model using whole blood as an alternative format. We then transferred both formats from 2-dimensional (2D) 96-well plates into a 3D microfluidics system, further mimicking the dynamics and structural microenvironment of a blood vessel. We used these human vasculature models to recapitulate the expected cytokine response to existing compounds and highlight the additional preclinical safety end points that can be investigated by using a 3D vessel, such as vascular leak. This proof-of-concept study demonstrates foundations for a scalable, physiologically relevant method for preclinical testing while reducing reliance on animal models.
Autor:innen und Institutionen
- Labcorp, Harrogate, United Kingdom.
- Labcorp, Huntingdon, United Kingdom.
Förderung
- Imperial College London
Zitieren
APA
Lund, E., Silvester, A., Thwaites, D., Bennour, Y., McKechnie, M., Beaumont, R., Munday, J., & Cooper, C. (2026). Development of autologous in vitro vascular models for use in preclinical biotherapeutic development. Blood Vessels, Thrombosis & Hemostasis, 3(2), 100143. https://doi.org/10.1016/j.bvth.2026.100143
Vancouver
Lund E, Silvester A, Thwaites D, Bennour Y, McKechnie M, Beaumont R, et al. Development of autologous in vitro vascular models for use in preclinical biotherapeutic development. Blood Vessels, Thrombosis & Hemostasis. 2026;3(2):100143. doi:10.1016/j.bvth.2026.100143
BibTeX
@article{Lund2026,
author = {Lund, Emma and Silvester, Alexander and Thwaites, Daniel and Bennour, Yasmin and McKechnie, Matthew and Beaumont, Ross and Munday, James and Cooper, Christopher},
title = {Development of autologous in vitro vascular models for use in preclinical biotherapeutic development},
journal = {Blood Vessels, Thrombosis & Hemostasis},
year = {2026},
volume = {3},
number = {2},
pages = {100143},
doi = {10.1016/j.bvth.2026.100143}
}
EUVIMED